Crispr/cas9 mRNA Therapy gene mutation SRD5A3 in Hepato-cellular carcinoma

A primary hepatocellular carcinoma (HCC, liver cancer for short) is a common malignant tumor that seriously threatens human life and health. It is the sixth most common malignant tumor in humans and ranks third in the global cause of cancer-related deaths. However, the relationship between the expression of SRD5A3 and platinum-based chemotherapy resistance of liver cancer remains to be further explored. Whether the inhibition of centrosome-associated protein SRD5A3 kinase gene by small interfering RNA can inhibit the occurrence and development of hepatocellular carcinoma, the effect of SRD5A3 on the biological behavior of liver cancer cells has not been reported at home and abroad. If the changes in SRD5A3 can be used to guide the diagnosis and treatment of hepatocellular carcinoma and evaluate the prognosis of patients, the related research of SRD5A3 will play a major role in the diagnosis and treatment of hepatocellular carcinoma. These researches use CRISPR/Cas9 (Clustered Regularly Inter Spaced Short Pali